---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-042600"
form_type: "8-K"
ticker: "HROW"
cik: "0001360214"
company_name: "HARROW, INC."
filed_at: "2024-10-28T23:59:59+00:00"
generated_at: "2026-05-30T09:37:32.193681+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Harrow draws $30M under Oaktree loan for Novartis Triescence milestone; amends credit terms

## Summary
- Drew $30M on Oct 25, 2024, under Oaktree Loan to partially fund $37M milestone to Novartis for Triescence commercial availability.
- Total drawn under Oaktree Loan now $107.5M; no additional borrowing capacity remains.
- Oaktree waived make-whole costs on the $30M draw if repaid before March 31, 2025.
- Second Amendment excludes the $30M draw from Total Leverage Ratio calculation.
- Milestone payment for Triescence was made on October 15, 2024.

## SEC filing metadata
- accession: 0001493152-24-042600
- form_type: 8-K
- ticker: HROW
- cik: 0001360214
- company_name: HARROW, INC.
- filed_at: 2024-10-28T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1360214/000149315224042600/0001493152-24-042600-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1360214/000149315224042600/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-042600
- JSON: https://secwatch.observer/filing/0001493152-24-042600.json
- Plain text: https://secwatch.observer/filing/0001493152-24-042600.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.